Future directions: Uncolytic viruses

Clinical Lung Cancer

Volumn 5, Issue 4, 2004, Pages 226-230

  You, Liang ^a   He, Biao ^a   Xu, Zhidong ^a   McCormick, Frank ^a   Jablons, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus; Combination therapy; Cytotoxicity; Herpes virus; Synergistic interaction; Vaccinia virus

Indexed keywords

ANTINEOPLASTIC AGENT; CELL RECEPTOR; CISPLATIN; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; E1A PROTEIN; E1B PROTEIN; FLUOROURACIL; G 207; GLYCOPROTEIN D; INITIATION FACTOR 2; K RAS PROTEIN; ONCOLYTIC VIRUS; ONYX 015; ONYX 411; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN P14ARF; PROTEIN P53; PV 701; RAS PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOBLASTOMA PROTEIN; RITUXIMAB; SMALLPOX VACCINE; THYMIDINE KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ONCOLYSATE; VIRUS DNA; VIRUS ONCOLYSATE; VIRUS RNA;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; CELL DESTRUCTION; CLINICAL TRIAL; DNA MODIFICATION; DRUG PROTEIN BINDING; DRUG TARGETING; FLU LIKE SYNDROME; GENE DELETION; GENETIC ENGINEERING; GENETIC IDENTIFICATION; HERPES SIMPLEX VIRUS 1; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; REOVIRUS; REVIEW; STANDARDIZATION; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REPLICATION; GENE THERAPY; GENETICS; METHODOLOGY; NEOPLASM; VIRUS;

GENE THERAPY; HUMANS; NEOPLASMS; VIRUS REPLICATION; VIRUSES;

EID: 1542330764     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.003     Document Type: Review

References (54)

1. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: ACS, 2004.
2. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998; 1378:F21-59.
3. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001; 1:130-141.
4. Antonio Chiocca E. Oncolytic viruses. Nat Rev Cancer 2002; 2:938-950.
5. Hermiston TW, Kuhn I. Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9:1022-1035.
6. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 1998; 23:291-296.
7. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677.
8. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54:73-87.
9. Carbone DP. The biology of lung cancer. Semin Oncol 1997; 24:388-401.
10. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991; 253:49-53.
11. Vonlanthen S, Heighway J, Tschan MP, et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncagene 1998; 17:2779-2785.
12. McCormick F. ONYX-015 selectivity and the p14ARF pathway. Oncogene 2000; 19:6670-6672.
13. Chen Y, Yu DC, Charlton D, et al. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11:1553-1567.
14. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-298.
15. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8:746-759.
16. Markert JM, Gillespie GY, Weichselbaum RR, et al. Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 2000; 10: 17-30.
17. Mastrangelo MJ, Eisenlohr LC, Gomella L, et al. Poxvirus vectors: orphaned and underappreciated. J Clin Invest 2000; 105:1031-1034.
18. Mastrangelo MJ, Maguire HC, Lattime EC. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol 2000; 465:391-400.
19. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001; 7:781-787.
20. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002; 13:641-652.
21. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20:2251-2266.
22. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-376.
23. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000; 6:1128-1133.
24. Yang CT, You L, Uematsu K, et al. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61:5959-5963.
25. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985-991.
26. McCormick F. Cancer therapy based on p53. Cancer J Sci Am 1999; 5:139-144.
27. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection. J Virol 1998; 72:9479-9490.
28. Hall AR, Dix BR, O'Carroll SJ, et al. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4:1068-1072.
29. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999; 73:2074-2083.
30. Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92:636-641.
31. You L, Yang CT. Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000; 60:1009-1013.
32. Tiainen M, Spitkovsky D, Jansen-Durr R, et al. Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms. Mol Cell Biol 1996; 16:5302-5312.
33. Sanchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 1996; 13:1083-1092.
34. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3:639-645.
35. Heise CC, Williams A, Olesch J, et al. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 1999; 6:499-504.
36. Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60:1193-1196.
37. Heise CC, Williams AM, Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999; 59:2623-2628.
38. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8:308-315.
39. Hecht JR, Bedford R, Abbruzzese JL, et al. A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clin Cancer Res 2003; 9:555-561.
40. Makower D, Rozenblit A, Kaufman H, et al. Phase II Clinical Trial of Intralesional Administration of the Oncolytic Adenovirus ONYX-015 in Patients with Hepatobiliary Tumors with Correlative p53 Studies. Clin Cancer Res 2003; 9:693-702.
41. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:1498-1504.
42. Post LE. Selectively replicating adenoviruses for cancer therapy: an update on clinical development. Curr Opin Investig Drugs 2002; 3:1768-1772.
43. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1:325-337.
44. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1:938-943.
45. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gme Ther 1999; 10:3013-3029.
46. Kucharczuk JC, Randazzo B, Chang MY, et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57:466-471.
47. Advani SJ, Chung SM, Yan SY, et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999; 59:2055-2058.
48. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001; 75:3314-3324.
49. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-874.
50. Puhlmann M, Gnant M, Brown CK, et al. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10:649-657.
51. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 1998; 17:3351-3362.
52. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-4689.
53. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282:1332-1334.
54. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62:1696-1701.